Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZS NASDAQ:BPTH NASDAQ:ONCS NASDAQ:PRPH NASDAQ:TLGT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.51-3.0%$3.52$3.96▼$12.00$10.26M1.557,305 shs7,193 shsBPTHBio-Path$0.17+3.3%$0.18$0.12▼$3.39$1.40M-0.03985,343 shs17,706 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsPRPHProPhase Labs$0.42-1.5%$0.36$0.22▼$3.55$17.85M-0.413.15 million shs354,394 shsTLGTTeligent$0.03$0.17▼$1.60N/AN/AN/A6,460 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris-3.84%+2.93%-0.85%+25.13%-49.20%BPTHBio-Path+3.32%-1.64%-14.76%+17.65%-90.82%ONCSOncoSec Medical0.00%0.00%0.00%0.00%0.00%PRPHProPhase Labs-1.47%+4.31%+16.67%+37.28%-87.80%TLGTTeligent0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/ABPTHBio-Path0.8255 of 5 stars0.05.00.00.00.60.01.3ONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/APRPHProPhase Labs0.6749 of 5 stars0.03.00.00.03.30.00.6TLGTTeligentN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/ABPTHBio-Path 0.00N/AN/AN/AONCSOncoSec Medical 0.00N/AN/AN/APRPHProPhase Labs 0.00N/AN/AN/ATLGTTeligent 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.65N/AN/A$14.99 per share0.23BPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/APRPHProPhase Labs$6.77M2.60N/AN/A$0.25 per share1.69TLGTTeligentN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)BPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%8/13/2025 (Estimated)ONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/APRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-184.38%-64.59%8/13/2025 (Estimated)TLGTTeligentN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest PRPH, TLGT, AEZS, ONCS, and BPTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025PRPHProPhase Labs-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93BPTHBio-PathN/A0.860.86ONCSOncoSec MedicalN/A0.890.89PRPHProPhase Labs0.301.030.98TLGTTeligentN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%BPTHBio-Path5.74%ONCSOncoSec Medical8.69%PRPHProPhase Labs9.45%TLGTTeligentN/AInsider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%BPTHBio-Path0.72%ONCSOncoSec Medical1.32%PRPHProPhase Labs9.60%TLGTTeligent0.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataBPTHBio-Path108.31 million5.73 millionOptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionablePRPHProPhase Labs13041.54 million37.55 millionOptionableTLGTTeligent2,357N/AN/AOptionablePRPH, TLGT, AEZS, ONCS, and BPTH HeadlinesRecent News About These CompaniesPAC Profile: TeligentSeptember 11, 2024 | opensecrets.orgOTopical pain reliever recalled for problem that can cause ‘severe morbidity, even death’June 7, 2023 | charlotteobserver.comCβ1 Adrenoceptor Agonists Market 2023 Newest Industry Data ... - StreetBuzzMay 13, 2023 | news.google.comNLidocaine Ointment Market Upcoming Trends, Size, Key Players ... - Taiwan NewsMay 13, 2023 | news.google.comNGlobal Mobile Value-Added Services (VAS) Industry Market Report ... - Industry TodayMay 11, 2023 | news.google.comNGlobal Clindamycin Phosphate Topical Market Analysis, Share ... - The Northwestern ExaminerMay 8, 2023 | news.google.comNDry Skin Treatment Market Products, Share, Types, Applications, Growth, Insights and Forecasts Report to 2028 - openPRMay 8, 2023 | news.google.comNMobile Value-Added Services (VAS) Market Size, Growth ... - Digital JournalMay 8, 2023 | news.google.comNMobile Value-Added Services (VAS) Market 2023 Global Insights ... - The Northwestern ExaminerMay 5, 2023 | news.google.comNEpinephrine For Allergy Treatment Market Dynamic Growth Factors ... - Digital JournalMay 3, 2023 | news.google.comNErythromycin Market with Focus on Growth Analysis, Production ... - Digital JournalMay 2, 2023 | news.google.comNFrom 2023 to 2031 Mobile Value-Added Services (VAS) Market ... - Digital JournalApril 29, 2023 | news.google.comNTremendous Growth Of Drugs To Relieve Paraneoplastic Pemphigus Market (2023-2030 )Industry Insights, SWOT Anal - openPRApril 28, 2023 | news.google.comNDrugs to Relieve Paraneoplastic Pemphigus Market 2023 Provides Top Companies Data, Top Key Players, Types and - openPRApril 26, 2023 | news.google.comNTopical Drug Delivery Market Production Capacity Estimates, Industry Size, Current Trend, Competition, Growth, - openPRApril 26, 2023 | news.google.comNTriamcinolone Market | Driving Factors, Industry Analysis ... - Taiwan NewsApril 24, 2023 | news.google.comNIDT Corp. Cl BApril 23, 2023 | wsj.comMobile Value-Added Services (VAS) Markets edge up Strategic ... - Digital JournalApril 17, 2023 | news.google.comNHikma Names Injectables Chief Mishlawi As CEO - Generics BulletinApril 12, 2023 | news.google.comNMobile Value-Added Services (VAS) Market is Anticipated to Shown ... - Digital JournalApril 10, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRPH, TLGT, AEZS, ONCS, and BPTH Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.51 -0.11 (-2.96%) As of 07/10/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Bio-Path NASDAQ:BPTH$0.17 +0.01 (+3.32%) As of 07/11/2025 12:51 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.OncoSec Medical NASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.ProPhase Labs NASDAQ:PRPH$0.42 -0.01 (-1.47%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$0.42 -0.01 (-1.77%) As of 07/11/2025 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Teligent NASDAQ:TLGTTeligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
